Skip to content
Menu

Glaukos Corporation GKOS

Full chart Compare
Set alert

Price alert · GKOS

All alert types
237.31 USD -0.79 (-0.33%)

Regular-session close

237.31 0.00 0.00%

After hours · Nov 20, 5:23 PM ET

233.40 Day range 244.55
95.20 52-week range 247.16
YTD
+110.18%
1 year
+149.28%

5D -15.84 (-6.32%)

240250MonTueWedThuFri234.73
Market cap
14.05B
Revenue (ttm)
690.33M
Profit margin
-24.60%
EPS (ttm)
-2.95
Shares out
59.20M
Forward P/E
169.77
YTD return
+110.18%
1-year return
+149.28%
50-day average
189.55
200-day average
149.71
Volume
1.09M
Avg volume
1.18M
Open
238.87
Previous close
238.10
Day's range
233.40 – 244.55
52-week range
95.20 – 247.16
Beta
0.68
Analysts
Strong Buy
Price target
243.85 (+2.8%)
Earnings date
Feb 16, 2027

Key statistics

Enterprise value
13.86B
Price / sales
20.38
Price / book
19.61
Revenue growth
58.00%
Free cash flow
52.60M
Total cash
336.70M
Total debt
105.15M
Return on equity
-22.84%
Short % of float
9.17%

Fundamental scorecard

7 of 25 checks passed on GKOS’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
GKOS Revenue — quarterly 211.03M
GKOS Net income — quarterly 2.02M
GKOS EPS — quarterly 0.03

Earnings

GKOS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 30, 20260.503———
Oct 28, 2026Sep 30, 2026-0.096360.47+0.57+587.75%
Jul 29, 2026Jun 30, 2026-0.21054-0.14+0.07+33.50%
Apr 29, 2026Mar 31, 2026-0.30-0.18+0.12+40.00%
Feb 17, 2026Dec 31, 2025-0.22-0.28-0.06-27.27%
Oct 29, 2025Sep 30, 2025-0.27-0.16+0.11+40.74%

Upgrades / downgrades

GKOS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 16, 2026BTIGmainBuyBuy
Oct 29, 2026HC Wainwright & Co.mainBuyBuy
Oct 29, 2026JP MorganmainOverweightOverweight
Oct 29, 2026CitigroupmainBuyBuy
Oct 29, 2026Truist SecuritiesmainBuyBuy
Oct 29, 2026Wells FargomainOverweightOverweight

About Glaukos Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
glaukos.com

News

Your note

Sign in to keep a note on GKOS — it syncs with the Stock Master app.

Insider holders

GKOS insider holders
InsiderRelationLatest transactionDateShares held
BURNS THOMAS WILLIAMChief Executive OfficerStock GiftMar 31, 20261,772,730
FOLEY MARK JDirectorStock Award(Grant)May 27, 202660,267
GILLIAM JOSEPH E.PresidentConversion of Exercise of derivative securityNov 15, 202671,602
HOFFMEISTER DAVID FDirectorStock Award(Grant)May 27, 202687,725
KLIMAN GILBERT H.DirectorConversion of Exercise of derivative securityNov 3, 202637,406
NAVRATIL TOMASOfficerConversion of Exercise of derivative securityOct 29, 202637,328

Institution ownership

GKOS institution ownership
Holder% heldSharesValueReported
Blackrock Inc.15.75%9,324,1832.22BSep 29, 2026
Janus Henderson Group Ltd.7.82%4,629,6871.10BSep 29, 2026
Vanguard Portfolio Management LLC5.58%3,303,897785.30MSep 29, 2026
Primecap Management Company5.20%3,076,200731.18MSep 29, 2026
FMR, LLC4.84%2,867,943681.68MSep 29, 2026
Vanguard Capital Management LLC4.30%2,546,798605.35MSep 29, 2026

Fund ownership

GKOS fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.94%3,513,860835.21MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%1,773,769421.61MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.53%1,496,000355.58MSep 29, 2026
VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund2.50%1,478,020351.31MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.16%1,280,092304.27MJun 29, 2026
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund1.69%1,001,435238.03MSep 29, 2026